As­traZeneca bags a ‘break­through’ for bruised check­point drug Imfinzi; In­otek CSO takes the helm at Flex

→ Just days af­ter a dam­ag­ing fail­ure for du­val­um­ab (Imfinzi) in a com­bi­na­tion ap­proach to lung can­cer, the FDA has des­ig­nat­ed As­traZeneca’s check­point in­hibitor as a “break­through” prod­uct de­serv­ing spe­cial treat­ment at the agency. Specif­i­cal­ly, the BTD is for lo­cal­ly-ad­vanced, un­re­sectable non-small cell lung can­cer (NSCLC) whose dis­ease has not pro­gressed fol­low­ing plat­inum-based chemora­di­a­tion ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER